Lannett to co-develop biosimilar insulin product with Chinese partner

Home/Pharma News | Posted 27/05/2016 post-comment0 Post your comment

US generics maker Lannett Company (Lannett) announced on 22 April 2016 plans to co-develop a biosimilar insulin product for the US market with its strategic partner in China, Yichang HEC Changjiang Pharmaceutical (Yichang), which is part of the HEC Group.

Insulin 2 V13E10

The product is currently in late stage development and, according to Arthur Bedrosian, chief executive officer of Lannett, Yichang has developed a proprietary process for manufacturing the insulin protein. The company also plans to build a dedicated facility for the manufacture of the insulin product for multiple markets around the world.

Lannett will manage the remaining clinical and regulatory steps specific for a US Food and Drug Administration (FDA) license to market. Lannett has the exclusive US marketing rights to the product. According to IMS, total US sales of insulin products were more than US$21 billion for the 12 months ending August 2015.

Lannett is currently collaborating with the HEC group on five projects, which include the development of certain products and a distribution agreement.

Related article
UCB sells generics unit to Lannett

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: HEC Pharma, Lannett

comment icon Comments (0)
Post your comment
Related content
Novartis is set to spin-off Sandoz
Guidance V13F21
Home/Pharma News Posted 16/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010